Johnson & Johnson’s single-dose coronavirus vaccine effectively prevents hospitalizations and deaths from the disease, the company said Friday.

The company reported its vaccine candidate was 72% effective in stopping moderate to severe coronavirus symptoms during phase 3 clinical trials.

The vaccine was 85% effective against severe illness, however, Johnson & Johnson officials said.

In comparison, vaccines from Pfizer/BioNTech and Moderna reported efficacy rates of 95% and 94.1%, respectively, before receiving emergency-use authorization from the Food and Drug Administration, though both of those vaccines require two doses.

Johnson & Johnson could request FDA authorization for its vaccine, developed in partnership with Janssen Pharmaceuticals, as early as next week, company officials said Friday.

Johnson & Johnson’s vaccine trials included roughly 44,000 people in the U.S., South Africa and several Latin American countries, though the efficacy data is based on just 468 cases of symptomatic COVID-19, the potentially deadly respiratory disease caused by the novel coronavirus.

The effectiveness also varied by region. While the vaccine was 72% effective against moderate to severe infection in the U.S., the percentage dropped to 66% worldwide. In South Africa, where a highly contagious variant of the virus has emerged, the effectiveness fell to 57%.

Nevertheless, Dr. Mathai Mammen, global head of pharmaceutical research and development at Johnson & Johnson, is optimistic about his company’s drug.

“Changing the trajectory of the pandemic will require mass vaccination to create herd immunity, and a single-dose regimen with fast onset of protection and ease of delivery and storage provides a potential solution to reaching as many people as possible,” Mammen said. “The ability to avoid hospitalizations and deaths would change the game in combating the pandemic.”

Did you like this story?
Would you like to receive articles like this in your inbox? Free!

WI Guest Author

This correspondent is a guest contributor to The Washington Informer.

Leave a comment

Your email address will not be published. Required fields are marked *